Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Healthcare Biotechnology
Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Trillium Therapeutics Inc.
Bullboard Posts
User Avatar Image
(0)
•••
Post by smattuon Jan 22, 2017 12:26pm
135 Views
Post# 25738704

Does investor know something more about Phase 1 results

Does investor know something more about Phase 1 resultsIn November the interim results from a Phase 1 study assessing the safety, tolerability and maximum tolerated dose of lead product candidate TTI-621 (SIRPalphaFc), a recombinant fusion protein that binds to CD47, a transmembrane protein that is overexpressed in many tumors and enables the cancer cells to avoid detection by the immune system. Since then stock continued to go down. I was thinking it was an over reaction but now looks like the pipleline is not looking like a blockbuster drug due to safety.
Any thoughts from any one ? Does anyone more .. I was told the IP is worth $7 bucks.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities